GLP1 Agonists and DPP4 Inhibitors How do they
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7
Incretin Therapy and Type 2 Diabetes Mellitus
Normalization of Diurnal Plasma Glucose Concentrations by Continuous IV GLP-1
Dose-Response Effectc of Exenatide on Plasma Glucose, Insulin, and Glucagon Concentration in T 2 DM
Effect of Exenatide on Glycemic Control in Metformin-Treated Type 2 Diabetes Subjects: 336 metformin-treated patients with type 2 diabetes Age: 53± 10 y; BMI: 34. 2± 5. 9 A 1 C: 8. 2± 1. 1% Protocol: • 4 -week placebo run-in • 4 weeks of exenatide (5 µg BID) or placebo • 26 weeks of exenatide (10 µg BID) or placebo • Metformin dose kept constant De. Fronzo RA, et al. Diabetes Care. 2005; 28: 1092 -1100.
Effect of Exenatide on A 1 C
Effect of Exenatide on Body Weight
Effect of Exenatide on Postprandial Glucose and Insulin Concentrations
Change in Weight by Quartile at 82 Weeks
Change in A 1 C as a Function of Change in Weight at 82 Weeks
Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks
Change in Blood Pressure as Function of Weight-Change Quartile at 82 Weeks
Exenatide Treatment: 3. 5 -Year Follow-up
Comparison of Exenatide vs Glargine on Glycemic Control in T 2 DM on MET/SU Therapy
Exenatide Reduces Postmeal ns Glucose Excursio
Once-Weekly Exenatide (LAR) vs Twice-Daily Exenatide Subjects: 295 T 2 DM on SU/Metformin; A 1 C >7. 0% Study Design: Once-weekly exenatide LAR (2 mg) vs twice-daily Exenatide (10 µg) for 30 wks Results: Decrement in A 1 C =1. 9% LAR QW vs 1. 5% Exenatide BID • 75% achieved A 1 C <7. 0% • 8 lb weight loss with both • Nausea occurred in only 20% of LAR=Long-acting release.
- Slides: 16